2 Winners for a Drug Development Future That Looks Nothing Like the Past

Genome sequencing and gene editing have been around for several years. However, new developments in each field are opening up doors that had been closed, and combining to usher in a new era for genomics. At the forefront are Pacific Biosciences of California (NASDAQ:PACB) and Beam Therapeutics (NASDAQ:BEAM). Each offers an upgrade from a technology that itself disrupted the status quo not long ago.